Q32 Bio reports Q1 2024 results; cash $135.3M, pipeline on track

Q32 Bio Inc.

2024-Q1 EPS reported -$6.33

Cash, equivalents, and short-term investments of $135.3M as of March 31, 2024; funding into mid-2026.
Completed enrollment in bempikibart Phase 2 alopecia areata trial; topline results expected Q4 2024.
ADX-097 renal basket Phase 2 trial to start H1 2024; initial data expected by year-end 2024.
Reverse merger with Homology Medicines closed in March 2024; concurrent $42M private placement.
Net income of $1.0M due to $15.9M gain on convertible note conversion; R&D expense $9.8M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Q32 Bio Inc. reported the quarter ended March 31, 2024 results: net income $1.0 million, EPS $1.03 basic net income per share and ($6.33) diluted net loss per share.

Period: the quarter ended March 31, 2024
Net income: $1.0 million
EPS: $1.03 basic net income per share and ($6.33) diluted net loss per share
Result: reported results

Exact text from the filing

Q32 Bio Inc. announced its financial results for the quarter ended March 31, 2024

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Q32 Bio Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-056256

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.